ArticleAnnals of clinical and translational neurology2022
Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh.
Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Neurofilament light chain improves clinical prognostic models for Guillain-Barré syndrome.Journal of neurology, neurosurgery, and psychiatry · 2025Trial
- Prognostic value of modified Erasmus Guillaiun Barre' syndrome outcome score (mEGOS) in an Italian cohort of patients: Challenges, insights and limitations.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Prognostic Nutritional Index as a Biomarker of Disease Severity and Long-Term Outcome in Guillain-Barré Syndrome.Journal of the peripheral nervous system : JPNS · 2025Observational
- Clinico-epidemiological profile and prediction of outcome in children with Guillain-Barre syndrome.Italian journal of pediatrics · 2025Observational
- Article
- Guillain-Barré syndrome.Nature reviews. Disease primers · 2024Article
- Predictors of respiratory failure in Guillain-Barré syndrome: a 22 year cohort study from a single Italian centre.European journal of neurology · 2024Article
- Predicting of Mechanical Ventilation and Outcomes by Using Models and Biomarker in Guillain-Barré Syndrome.Neurology and therapy · 2023Article
- Construction and evaluation of a prognostic prediction model based on the mEGOS score for patients with Guillain-Barré syndrome.Frontiers in neurology · 2023Article
- Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh.Annals of clinical and translational neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveWe have assessed and improved the performance of the modified Erasmus GBS Outcome Score (mEGOS) among patients with Guillain-Barré syndrome (GBS) from Bangladesh.
methodsValidation cohort consisted of patients with GBS from two prospective cohort studies in Bangladesh. Poor outcome was defined as being unable to walk independently at week 4 and week 26. We excluded patients able to walk independently, patients who died within the first week, or with missing GBS disability scores. Performance of mEGOS at entry and week 1 was determined based on the discriminative ability (ability to differentiate between patients able and unable to walk independently; measured using the area under the receiver operating characteristic curves [AUC]) and calibration (observed probability versus predicted probability of poor outcome).
resultsA total of 506 patients aged ≥6-year-old were enrolled, with 471 and 366 patients included in mEGOS validation analysis at entry and week 1, respectively. The AUC values for predicting poor outcome (1) at week 4 were 0.69 (mEGOS entry) and 0.78 (mEGOS week 1) and (2) at week 26 were 0.67 (mEGOS entry) and 0.70 (mEGOS week 1). Mean predicted probabilities of poor outcome corresponded with observed outcomes except for the probability of poor outcome at week 4 which was overestimated by mEGOS week 1. This was resolved by updating the model intercept.
interpretationThe mEGOS shows valid outcome predictions among patients with GBS from Bangladesh. The model can aid the identification of patients at high risk of poor outcome and help to adequately allocate healthcare resources in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.